Who is sponsoring NCT04063566?

NCT04063566 is sponsored by University College, London.

What drugs are being tested in NCT04063566?

Interventions in NCT04063566: Magnetic Resonance Imaging (MRI), Prostate-specific antigen (PSA) test.

What condition does NCT04063566 study?

NCT04063566 studies Prostate Cancer Screening, Prostate Cancer.

Is NCT04063566 still recruiting?

NCT04063566 is currently completed. Last updated 15 October 2021.

Last reviewed 2021-10-15 · How we verify

NCT04063566

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ReIMAGINE Prostate Cancer Screening

Completed NA Last updated 15 October 2021

What this trial tests

NA trial testing Magnetic Resonance Imaging (MRI) in Prostate Cancer Screening in 309 participants. Completed in 30 September 2021.

Timeline

21 October 2019

Primary endpoint
30 July 2021

30 September 2021

Quick facts

Lead sponsor	University College, London
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	screening
Enrollment	309
Start date	21 October 2019
Primary completion	30 July 2021
Estimated completion	30 September 2021
Sites	1 location across United Kingdom

Drugs / interventions tested

Magnetic Resonance Imaging (MRI)
Prostate-specific antigen (PSA) test

Conditions studied

Prostate Cancer Screening — all drugs for Prostate Cancer Screening →
Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

University College, London

Who can join

Adults 50 to 75, male only, with Prostate Cancer Screening or Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Single site study to assess the feasibility of prostate cancer screening using an invitation for a prostate MRI scan via GP practices. This feasibility study will assess the acceptability of an MRI as a prostate cancer screening assessment and assess the prevalence of MRI defined suspicious lesions and cancer in men across a spectrum of PSA results.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Genetic Landscape of Prostate Cancer Conspicuity on Multiparametric Magnetic Resonance Imaging: A Systematic Review and Bioinformatic Analysis.
Norris JM, Simpson BS, Parry MA, Allen C, et al · · 2020 · cited 36× · PMID 33000006 · DOI 10.1016/j.euros.2020.06.006
The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening.
Benafif S, Ni Raghallaigh H, McGrowder E, Saunders EJ, et al · · 2022 · cited 29× · PMID 34214236 · DOI 10.1111/bju.15535
Genetic predisposition to prostate cancer: an update.
Ni Raghallaigh H, Eeles R. · · 2022 · cited 29× · PMID 33486571 · DOI 10.1007/s10689-021-00227-3
Prevalence of MRI lesions in men responding to a GP-led invitation for a prostate health check: a prospective cohort study.
Moore CM, Frangou E, McCartan N, Santaolalla A, et al · · 2023 · cited 25× · PMID 39886504 · DOI 10.1136/bmjonc-2023-000057
MRI as a screening tool for prostate cancer: current evidence and future challenges.
Würnschimmel C, Chandrasekar T, Hahn L, Esen T, et al · · 2023 · cited 22× · PMID 35226140 · DOI 10.1007/s00345-022-03947-y
ReIMAGINE Prostate Cancer Screening Study: protocol for a single-centre feasibility study inviting men for prostate cancer screening using MRI.
Marsden T, Lomas DJ, McCartan N, Hadley J, et al · · 2021 · cited 17× · PMID 34593491 · DOI 10.1136/bmjopen-2020-048144
Comparison of Multiparametric Magnetic Resonance Imaging with Prostate-Specific Membrane Antigen Positron-Emission Tomography Imaging in Primary Prostate Cancer Diagnosis: A Systematic Review and Meta-Analysis.
Zhao Y, Simpson BS, Morka N, Freeman A, et al · · 2022 · cited 15× · PMID 35884558 · DOI 10.3390/cancers14143497
Update from the ReIMAGINE Prostate Cancer Screening Study NCT04063566: Inviting Men for Prostate Cancer Screening Using Magnetic Resonance Imaging.
Marsden T, McCartan N, Hadley J, Tuck S, et al · · 2021 · cited 7× · PMID 33896710 · DOI 10.1016/j.euf.2021.03.027

Verify or expand the search:

Other trials of Magnetic Resonance Imaging (MRI)

Trials testing the same drug.

NCT07226453 — Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma · Phase 2 · not yet recruiting
NCT07346170 — Short Interval Postoperative Stereotactic Body Radiation Therapy (SBRT) After Surgical Intervention for Spine Metastases · NA · not yet recruiting
NCT07110246 — Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas · Phase 2 · recruiting
NCT07185958 — Dual Energy CT - a Tool for Delineation of Tumor and Organs at Risk in Radiotherapy · not yet recruiting
NCT06492057 — Electromyostimulation (EMS) of Astronauts in Spaceflight (Easymotion-2) · NA · enrolling by invitation

Other recruiting trials for Prostate Cancer Screening

Currently open trials in the same condition.

NCT06626022 — Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging. · Phase 3 · recruiting
NCT06923657 — PSMA PET/MRI-Guided Prostate Biopsy for PI-RADS ≤3 and Prior Negative Biopsy · NA · recruiting
NCT05608694 — MRI Screening in Men at High Risk of Developing Prostate Cancer · NA · recruiting

Other University College, London trials

Trials by the same sponsor.

NCT07386652 — Intensive Comprehensive Aphasia Programme for People With Post-Stroke Aphasia · NA · not yet recruiting
NCT06924086 — The Children's Adaptive Deep Brain Stimulation for Epilepsy Trial · NA · recruiting
NCT07386678 — Study of Imaging and Molecular Biomarkers in Uncomplicated Rhegmatogenous Retinal Detachment · not yet recruiting
NCT07414940 — ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium · Phase 1, PHASE2 · not yet recruiting
NCT07214454 — TCDS for the Treatment of Chronic Migraine · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04063566 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University College, London
Last refreshed: 15 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04063566.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing